Lopes de Menezes D - Search Results

1

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.

Döhner H, Wei AH, Roboz GJ, Montesinos P, Thol FR, Ravandi F, Dombret H, Porkka K, Sandhu I, Skikne B, See WL, Ugidos M, Risueño A, Chan ET, Thakurta A, Beach CL, Lopes de Menezes D. Döhner H, et al. Among authors: lopes de menezes d. Blood. 2022 Oct 13;140(15):1674-1685. doi: 10.1182/blood.2022016293. Blood. 2022. PMID: 35960871 Free PMC article. Clinical Trial.

2

Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes.

Garcia-Manero G, Santini V, Almeida A, Platzbecker U, Jonasova A, Silverman LR, Falantes J, Reda G, Buccisano F, Fenaux P, Buckstein R, Diez Campelo M, Larsen S, Valcarcel D, Vyas P, Giai V, Olíva EN, Shortt J, Niederwieser D, Mittelman M, Fianchi L, La Torre I, Zhong J, Laille E, Lopes de Menezes D, Skikne B, Beach CL, Giagounidis A. Garcia-Manero G, et al. Among authors: lopes de menezes d. J Clin Oncol. 2021 May 1;39(13):1426-1436. doi: 10.1200/JCO.20.02619. Epub 2021 Mar 25. J Clin Oncol. 2021. PMID: 33764805 Free PMC article. Clinical Trial.

3

CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.

Lopes de Menezes DE, Peng J, Garrett EN, Louie SG, Lee SH, Wiesmann M, Tang Y, Shephard L, Goldbeck C, Oei Y, Ye H, Aukerman SL, Heise C. Lopes de Menezes DE, et al. Clin Cancer Res. 2005 Jul 15;11(14):5281-91. doi: 10.1158/1078-0432.CCR-05-0358. Clin Cancer Res. 2005. PMID: 16033847

4

A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.

Chi KN, Gleave ME, Klasa R, Murray N, Bryce C, Lopes de Menezes DE, D'Aloisio S, Tolcher AW. Chi KN, et al. Among authors: lopes de menezes de. Clin Cancer Res. 2001 Dec;7(12):3920-7. Clin Cancer Res. 2001. PMID: 11751483 Clinical Trial.

5

In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models.

Lee SH, Lopes de Menezes D, Vora J, Harris A, Ye H, Nordahl L, Garrett E, Samara E, Aukerman SL, Gelb AB, Heise C. Lee SH, et al. Among authors: lopes de menezes d. Clin Cancer Res. 2005 May 15;11(10):3633-41. doi: 10.1158/1078-0432.CCR-04-2129. Clin Cancer Res. 2005. PMID: 15897558

6

Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.

Lopes de Menezes DE, Denis-Mize K, Tang Y, Ye H, Kunich JC, Garrett EN, Peng J, Cousens LS, Gelb AB, Heise C, Wilson SE, Jallal B, Aukerman SL. Lopes de Menezes DE, et al. J Immunother. 2007 Jan;30(1):64-74. doi: 10.1097/01.cji.0000211315.21116.07. J Immunother. 2007. PMID: 17198084

7

CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.

Tse AN, Rendahl KG, Sheikh T, Cheema H, Aardalen K, Embry M, Ma S, Moler EJ, Ni ZJ, Lopes de Menezes DE, Hibner B, Gesner TG, Schwartz GK. Tse AN, et al. Among authors: lopes de menezes de. Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):591-602. doi: 10.1158/1078-0432.CCR-06-1424. Clin Cancer Res. 2007. PMID: 17255282

8

Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts.

Lopes de Menezes DE, Mayer LD. Lopes de Menezes DE, et al. Cancer Chemother Pharmacol. 2002 Jan;49(1):57-68. doi: 10.1007/s00280-001-0385-3. Cancer Chemother Pharmacol. 2002. PMID: 11855753

9

Combined treatment of Bcl-2 antisense oligodeoxynucleotides (G3139), p-glycoprotein inhibitor (PSC833), and sterically stabilized liposomal doxorubicin suppresses growth of drug-resistant growth of drug-resistant breast cancer in severely combined immunodeficient mice.

Lopes de Menezes DE, Hu Y, Mayer LD. Lopes de Menezes DE, et al. J Exp Ther Oncol. 2003 Mar-Apr;3(2):72-82. doi: 10.1046/j.1359-4117.2003.01075.x. J Exp Ther Oncol. 2003. PMID: 12822513

10

Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.

Lopes de Menezes DE, Hudon N, McIntosh N, Mayer LD. Lopes de Menezes DE, et al. Clin Cancer Res. 2000 Jul;6(7):2891-902. Clin Cancer Res. 2000. PMID: 10914739

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

14 results

Search Page